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Abstract
Introduction: Indole-3-carbinol (I3C), an autolysis product of glucosinolates present in cruciferous vegetables, and
its dimeric derivative (3,3’-DIM) have been indicated as promising agents in preventing the development and
progression of breast cancer. We have recently shown that I3C cyclic tetrameric derivative CTet formulated in g-
cyclodextrin (g-CD) efficiently inhibited cellular proliferation in breast cancer cell lines. This study aims to analyze
the mechanisms involved in the in vitro inhibition of cell proliferation and to evaluate the in vivo antitumor activity
of CTet in a xenograft study.
Methods: Estrogen receptor-positive MCF-7 and triple-negative MDA-MB-231 breast cancer cell lines were exposed
to CTet to evaluate cell cycle perturbation (propidium iodide staining and cytofluorimetric acquisition), induction of
autophagic morphological features (co-localization of LC3b autophagosome marker and LAMP2a lysosome marker
by immunofluorescence) and changes in protein expression (immunoblot and microarray-based gene expression
analyses). To test the in vivo efficacy of CTet, female athymic nude mice inoculated with MCF-7 cells were i.p.
treated with 5 mg/kg/day of CTet for five days/week for two weeks and the tumor mass was externally monitored.
Results: CTet induced accumulation in G2/M phase without evidence of apoptotic response induction in both cell
lines tested. In triple-negative MDA-MB-231 the autophagic lysosomal activity was significantly up-regulated after
exposure to 4 μM of CTet for 8 hours, while the highest CTet concentration was necessary to observe autophagic
features in MCF-7 cells. The inhibition of Akt activity and p53-independent p21/CDKN1A and GADD45A
overexpression were identified as the main molecular events responsible for CTet activity in MCF-7 and p53-mutant
MDA-MB-231 cells. In vivo, CTet administration was able to significantly inhibit the growth of MCF-7
xenotransplanted into nude mice, without adverse effect on body weight or on haematological parameters.
Conclusions: Our data support CTet formulated with g-CD as a promising and injectable anticancer agent for both
hormone-responsive and triple-negative breast tumors.
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Breast cancer is one of the most common malignancies
in industrialized countries and is characterized by dis-
tinct classes of tumors that respond differently to tar-
geted therapies such as selective estrogen receptor
modulator (SERM) treatments (for example, tamoxifen)
in estrogen receptor (ER)-positive breast cancer or
monoclonal antibodies (for example, trastuzumab) in
HER2/Neu-positive breast cancer. However, about 10%
to 15% of breast cancers do not express ER, progester-
one receptor (PR), and HER2/Neu receptor [1,2]. This
subgroup, the so-called triple-negative category, is asso-
ciated with poor prognosis because of its resistance to
therapy. Its management includes the use of standard
treatment such as platinum-based therapy, anthracy-
cline, and taxanes; nevertheless, it is frequently asso-
ciated with local and systemic relapse [2]. Therefore, a
critical problem in the clinical strategies for the manage-
ment of breast cancer is the development of molecules
with effective activity in the treatments of hormone-
responsive as well as triple-negative tumors. Several
clinical trials assessing various therapeutic options,
including the use of inhibitors of specific molecular tar-
gets such as poly-(ADP-ribose)-polymerase (PARPs) or
the mammalian target of rapamycin (mTOR), used as
monotherapy or combined with traditional chemother-
apy, are currently ongoing [1]. Owing to their implica-
tion in several cell responses such as regulation of cell
growth, survival, and apoptosis, phosphatidylinositol
3-kinase (PI3K) and the downstream Akt/mTOR path-
way represent potential targets for treatment of triple-
negative breast cancer [2,3].
Cruciferous vegetable consumption has been asso-
ciated with lower cancer risk in several epidemiological
and dietary studies [4-6]. The chemopreventive proper-
ties of these vegetables are attributed to the antitumor
activity of indole-3-carbinol (I3C) and its metabolic deri-
vatives, which have shown great potential for both pre-
vention and treatment of cancer through numerous
mechanisms such as induction of apoptosis and cell
cycle arrest, antiestrogenic activity, gene expression
modulation, and prevention of carcinogen-DNA adduct
formation [7,8]. It has also been reported that I3C and
its major condensation product 3,3’-DIM inactivate the
Akt signaling pathway in breast cancer cells [9-11].
Nevertheless, the development of I3C as a therapeutic
agent is limited by several factors such as its easy con-
version into many polymeric products in vivo [12].
These compounds have some common targets but have
also been demonstrated to have distinct biological
effects on breast cancer cells [13,14] and the relatively
high concentrations necessary to inhibit the expression
of CDK6 and to induce cell cycle arrest in breast cancer
(from 50 to 200 μM) [15,16].
As alternatives to I3C as a chemotherapeutic agent for
the treatment of breast cancer, several I3C derivatives
characterized by higher antiproliferative properties have
recently been proposed [7,17-19]. I3C cyclic tetrameric
derivative CTet (5,6,11,12,17,18,23,24-octahydrocyclodo-
deca[1,2-b:4,5-b’:7,8-b”:10,11-b’”]tetraindole) (Figure 1) is
an anticancer molecule that has been shown to exert
interesting antiproliferative activity in both MCF-7 and
MDA-MB-231 breast cancer cell lines [20]. Lucarini and
colleagues [21] have optimized a straightforward, repro-
ducible, and scalable CTet synthesis. Moreover, to
improve bioavailability, they have optimized a formula-
tion that is based on gamma-cyclodextrin (g-CD) aqu-
eous solution and that is about 10-fold more active with
respect to the first preparation [20].
In this study, we analyze the biological responses in
terms of cell cycle perturbations and autophagy induc-
tion in both ER-positive (MCF-7) and triple-negative
(MDA-MB-231) breast cancer cell lines exposed to CTet
obtained by a new synthetic procedure. We also charac-
terize the molecular mechanisms leading to the inhibi-
tion of cell proliferation by using microarray-based gene
expression analysis. We identified the overexpression of
p21/CDKN1A (cyclin-dependent kinase inhibitor 1A) as
the strongest molecular event induced by CTet treat-
ment; the inhibition of Akt activity, revealed in CTet-
treated cells, could be responsible for p21/CDKN1A
overexpression in MCF-7 and p53-mutant MDA-MB-
231 cells. Finally, the toxicity and antitumoral efficacy of
the g-CD-formulated CTet, obtained in a preliminary
xenograft study, are discussed.
Materials and methods
Chemistry
All reagents, with the exception of g-CD (CAVAMAX
®
W8; Wacker, Munich, Germany), were purchased from
Sigma-Aldrich (St. Louis, MO, USA) or Carlo Erba
(Rodano, Italy) and were the highest quality reagents
that were commercially available. Solvents were Carlo
Erba analytic grade. Melting point, high-performance
liquid chromatography/mass spectrometry (HPLC/MS),
1H-NMR, and
13C-NMR were determined as in [21].
Purification of the crude material was carried out as
in [21]. Thin layer chromatography analyses were
performed as in [21].
Synthesis of CTet
To a solution of 3-[(1H-indol-2-yl)methyl]-1H-indole
(2,3’-DIM) [22] (0.246 g, 1 mmol) and 37% aqueous for-
maldehyde (0.122 mL, 1.46 mmol) in methanol (10 mL),
96% sulphuric acid (0.063 mL) was added, and the mix-
ture was refluxed in the dark for 1 hour. After cooling,
the purple mixture was concentrated in vacuo in the
dark. Purification of the resulting deep-purple solid by
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graphies (cyclohexane/EtOAc 8:2) that were protected
from light gave a white solid consisting (HPLC/MS) of a
2:1 mixture of CTr (5,6,11,12,17,18-esahydrocyclonona
[1,2-b:4,5-b’:7,8-b”]triindole) and CTet (yield: 45%, 0.117
g), which was recrystallized from acetone (12 mL). CTet
was obtained as a pure white solid. CTet yield was 16%
(0.041 g). Melting point,
1H-NMR, and
13C-NMR are in
accordance with the literature [21].
Cell culture
The human breast carcinoma ER
+ (MCF-7, BT-474) and
triple-negative (MDA-MB-231, BT-20) cell lines were cul-
tured in Dulbecco’sm o d i f i e dE a g l e ’s medium supplemen-
ted with 10% fetal calf serum, 2 mM L-glutamine, 10 g/L
non-essential amino acid, 50 mg/L streptomycin, 1,000
U/L penicillin, and 10 mg/L insulin (in MCF-7 cells) at
37°C in a humidified incubator with 5% CO2. For the
in vivo experiments, MCF-7 cells were cultured in com-
plete medium supplemented with 1 nM b-estradiol
17-cypionate for 2 weeks. All cell culture materials were
purchased from Sigma-Aldrich. CTet was formulated
with aqueous g-CD solution as reported by Lucarini and
colleagues [21]. In all experiments, 10 μL of the concen-
trated agent was added to 1 mL of cell culture medium
(vehicle control, 10 μL of aqueous solution of g-CD).
Cell treatments
Cell proliferation was evaluated by using a [
3H]thymi-
dine (Sigma-Aldrich) incorporation assay. Cells were
seeded at a density of 30,000 per well in 24-well tissue
culture plates and allowed to attach overnight. Duplicate
samples were treated for 72 hours with increasing con-
centrations of CTet (from 0.5 to 8.0 μM). During the
last 5 hours of treatment, cells were pulsed with 3 μCi/
well of [
3H]thymidine (25 Ci/mmol) and processed as
reported by Brandi and colleagues [20]. Briefly, cells
were washed three times with ice-cold trichloroacetic
acid (10% wt/vol) and lysed with 300 μLo f0 . 3N
NaOH. Aliquots (150 μL) of lysate were transferred into
scintillation vials and processed for liquid scintillation
counting. The results are expressed as the percentage of
average count-per-minute value in drug-treated samples
compared with control samples.
In a set of experiments, one batch of CTet was sus-
pended in pure ethanol and aliquoted to evaluate the
activity in different storing conditions. One aliquot was
diluted in g-CD and immediately tested in the antiproli-
ferative assay. Three aliquots were stored at the follow-
ing conditions: (a) room temperature and exposed to
light, (b) room temperature and protected from light,
and (c) +4°C and protected from light. Three other ali-
quots were diluted 1:10 in aqueous solutions of g-CD
and stored at the same conditions. The antiproliferative
activity was evaluated in MCF-7 cells by using a [
3H]
thymidine incorporation assay at different time points
up to 1 year.
For the gene expression, immunoblot, and cell cycle
analyses, breast cancer cells were plated in six-well cul-
ture plates at a density of 150,000 cells per well and
were cultured overnight. Cellular treatments were con-
ducted at increasing concentrations of CTet or vehicle
control for 24 and 48 hours. Cell survival was then eval-
uated by trypan blue dye exclusion assay, and after
washing in phosphate-buffered saline (PBS), the cells
were pelletted by centrifugation and immediately used
for cell cycle analysis or stored at -20°C (for successive
immunoblot or gene expression analyses). Cellular pel-
lets prepared for gene expression analysis were stored
with 300 μL of RNA-later (Sigma-Aldrich).
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Figure 1 Synthesis of CTet. Homo-coupling of 2,3’-DIM in the presence of formaldehyde in acidic conditions is shown. Methanol was the
solvent, and the mixture was refluxed for 1 hour in the dark. CTet, indole-3-carbinol cyclic tetrameric derivative.
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Quantitative determinations of CTet were performed by
using an HPLC-UV method (JASCO Model PU-980).
The compound was separated at room temperature on a
Tracer Excel 120 ODSA 5 μm 15 × 0.46 column pro-
tected by a guard column (Pelliguard LC-18, 20 mm ×
4.6 mm internal diameter, 40 μm); columns were from
Teknokroma (Barcelona, Spain). CTet was quantified by
UV detection at 280 nm. The volume injected was 50
μL. The mobile phase consisted of two eluents: 100%
H2O (buffer A) and 100% acetonitrile (buffer B).
CTet was eluted at a flow rate of 1.0 mL/minute and
the following steady gradient program: 100% buffer A
for 3 minutes, taken to 40% buffer B over the next 12
minutes, and rising to 80% buffer B from 15 to 25 min-
utes. This condition was held for 5 minutes, and the
gradient was returned to 100% buffer A in 5 minutes.
Cell cycle analysis
Cell cycle was analyzed by means of the propidium
iodide staining procedure previously reported [23].
Briefly, cells were fixed in ice-cold 70% ethanol solution
(16 hours at +4°C) and stained in propidium iodide
solution (0.1% sodium citrate, 0.1% Triton X-100, 250
μg/mL RNase A, and 50 μg/mL propidium iodide).
Cytofluorimetric acquisitions and sample analysis were
performed with a Partec PAS flow cytometer (Partec,
Münster, Germany) and FlowJo 8.6.3 software (TreeStar,
Inc., Ashland, OR, USA), respectively.
Autophagy detection by immunofluorescence analyses
MCF-7 and MDA-MB-231 cells were grown in com-
plete medium on glass coverslips in six-well plates.
After 24 hours of attachment, cells were treated with
CTet for 4, 8, 12, and 24 hours. At the end of each
treatment, cells were fixed with PBS (containing 4%
formaldehyde) for 15 minutes and permeabilized with
methanol/acetone solution for 15 minutes at room
temperature. To assess the co-localization of LC3b
(microtubule-associated protein 1 light chain 3) with
the lysosome marker LAMP2a (lysosome-associated
membrane protein type 2a), cells were incubated with a
mixture containing the anti-LC3b (Sigma-Aldrich) and
LAMP2a (Abcam, Cambridge, UK) primary antibodies,
washed, and then probed with goat anti-rabbit Alexa-
Fluor498 and goat anti-mouseA l e x a F l u o r 5 9 4s e c o n d -
ary antibodies. Nuclei were counterstained with 0.1 μg/
mL 4’-6-diamidino-2-phenylindole (DAPI). Images
were acquired by a Nikon Eclipse E600 microscope
(Nikon Corporation, Tokyo, Japan) with ACT-1 soft-
ware and were processed with an Adobe Photoshop
Image Reader 7.0 (Adobe Systems Incorporated, San
Jose, CA, USA).
Gene expression analysis
RNA extraction and microarray analysis
Whole genome microarray analysis was performed on a
CodeLink Expression Bioarray System (GE Healthcare,
Piscataway, NJ, USA) on either MCF-7 or MDA-MB-
231 cells treated with 6 and 12 μM CTet for 24 hours.
Total RNA was purified from treated and control cells
by using an RNeasy plus kit (Qiagen, Hilden, Germany).
The RNA was quantified spectrophotometrically by
using a Nanodrop ND-1000 (Thermo Fisher Scientific,
Waltham, MA, USA); RNA integrity was evaluated
on an Experion automated gel electrophoresis system
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). Biotin-
labeled cRNA was synthesized by using a CodeLink iEx-
press Assay reagent kit (GE Healthcare) in accordance
with the protocols of the manufacturer. Biotin-labeled
cRNA obtained from each control or treated biological
sample was fragmented and hybridized against three
independent arrays (10 μg each) at 37°C for 22 hours
(that is, three replicates for each biological sample).
After hybridization, the arrays were washed, stained
with Cy5-streptavidin, and scanned with a ScanArray
GX scanner (PerkinElmer, Waltham, MA, USA) with a
resolution of 5 μm.
The image files generated by the scanner were pro-
cessed with CodeLink Expression Analysis software (GE
Healthcare). Normalized data from the CodeLink soft-
ware package were analyzed with GeneSifter software
(Geospiza, Inc., Seattle, WA, USA) [24] for statistical
validation and data mining. This comprehensive soft-
ware also generated gene ontology (GO) and z-score
reports. The z-score is useful for ranking GO terms by
their relative amounts of gene expression changes. Posi-
tive z-scores indicate GO terms with a number of differ-
entially expressed genes higher than expected by chance,
whereas negative z-scores indicate GO terms with a
number of differentially expressed genes lower than
expected by chance [25]. The whole data set obtained
from the two experiments on MCF-7 and MDA-MB-
231 cells, both including technical replicates for each
control and treated sample, was subjected to analysis of
variance (ANOVA) and 5% false discovery rate calcula-
tion [26]. The cutoff parameters for differential gene
expression were P value of 0.01 and fold change thresh-
old of 2. Microarray data are available in the MIAME
(minimum information about a microarray experiment)-
compliant ArrayExpress database [27] (accession num-
ber [ArrayExpress:E-MEXP-2989]).
Quantitative real-time polymerase chain reaction
Real-time polymerase chain reaction (RT-PCR) was used
to validate the gene expression profiles observed in the
CodeLink microarray experiments. cDNA was synthe-
sized from the same total RNA used for microarray
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System for RT-PCR (Invitrogen Corporation, Carlsbad,
CA, USA) with oligo-dT priming was used. Primers for
amplification of p27/CDKN1B were p27F 5’-GCAG-
GAATAAGGAAGCGACCT-3’ and p27R 5’-TCCACA-
GAACCGGCATTTG-3’, whereas primers for the
amplification of p21/CDKN1A and GADD45A (growth
arrest and DNA-damage-inducible protein alpha),
together with primers for the amplification of house-
keeping genes ACTB (actin-b)a n dGAPDH (glyceralde-
hyde-3-phosphate dehydrogenase), have been described
elsewhere [23]. All primer pairs spanned an intron to
avoid amplification of contaminating genomic DNA.
RT-PCRs were performed in triplicate in a final volume
of 25 μL by using SYBR green PCR master mix (Applied
Biosystems, Foster City, CA, USA) with 200 nM primers
in a RotorGene 6000 instrument (Corbett Life Science,
Sydney, Australia). The cycling protocol was 95°C for
10 minutes followed by 40 cycles at 95°C for 10 sec-
onds and 60°C for 45 seconds. At the end of each run,
a melting curve analysis from 55°C to 90°C was per-
formed to ensure the absence of primer dimers or non-
specific products. Fold changes were calculated by
using the comparative quantification application of the
RotorGene 6000 software. RT-PCR-based gene expres-
sion analysis was also repeated on two new sets of
biological samples, from both MCF-7 and MDA-MB-
231 cells.
Immunoblot analysis
Untreated and CTet-treated cells were lysed for 20 min-
utes on ice with 20 mM HEPES (pH 7.9), 25% glycerol,
0.42 M NaCl, 0.2 mM EDTA, 1.5 mM MgCl2,0 . 5 %
Nonidet P-40, and 1× Complete protease inhibitor cock-
tail (Roche Diagnostics Ltd., Mannheim, Germany). Cell
lysate was frozen and thawed twice and clarified by cen-
trifugation at 12,000 revolutions per minute (rpm) for
10 minutes at 4°C. The subcellular fraction was obtained
as follows: cells were lysed for 10 minutes on ice with
10 mM HEPES (pH 7.9), 1.5 mM MgCl2,1 0m MK C l ,
1m ME D T A ,1m MN a 3VO4,1m MN a F ,1m MD T T ,
0.1% Nonidet P-40, and 1× Complete protease inhibitor
cocktail. Samples were then centrifuged at 12,000 rpm
for 10 minutes at 4°C to obtain the cytosolic fraction
(supernatant); the pellet was resuspended in 20 mM
HEPES (pH 7.9), 25% glycerol, 0.42 M NaCl, 0.2 mM
EDTA, 1.5 mM MgCl2,1m MN a 3VO4,1m MN a F ,
1 mM DTT, and 1× Complete protease inhibitor cock-
tail, incubated 20 minutes on ice, and centrifuged at
12,000 rpm for 10 minutes at 4°C to obtain the nuclear
fraction (supernatant).
Proteins extracted were fractionated on 12% (p27 and
p21) and 7.5% (Akt, phospho-Akt, and FOXO3a) SDS-
PAGE and then electrically transferred to Trans-Blot
transfer medium (0.2 μm) nitrocellulose membrane
(Bio-Rad Laboratories, Inc.). Blots were incubated with
anti-p27 (1:500) and anti-p21 (1:200) antibodies pur-
chased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA), anti-Akt and anti-phospho-Akt(Ser473)
antibodies purchased from Cell Signaling Technology
(Danvers, MA, USA), and anti-FKHRL1/FOXO3a
(1:1,000) antibody purchased from Upstate (now part of
Millipore Corporation, Billerica, MA, USA) overnight at
4°C and then 1 hour at room temperature with peroxi-
dase-conjugated secondary antibody. Blots were treated
with enhanced chemiluminescence reagents, and all of
the proteins were detected and quantitated by Chemi-
Doc System (Bio-Rad Laboratories, Inc.). Equal protein
loading was confirmed by the level of actin protein pre-
sent in the membrane tested with anti-actin antibody
1:500 (Sigma-Aldrich).
In vivo tumor growth inhibition
Housing and treatment of mice were in compliance with
the Guide for the Care and Use of Laboratory Animals
by Ministero della Sanità D.L. 116 (1992) and approved
by the university committee for animal experiments.
Female athymic Crl:CD-1-nu/nuBR nude mice (4 weeks
of age) (Charles River Laboratories, Milan, Italy) were
housed under pathogen-free conditions. The mice were
acclimated for 1 week.
Beta-estradiol 17-cypionate (Sigma-Aldrich) was intra-
muscularly injected at 3 mg/kg 1 week before MCF-7
cells were transplanted into the animal and then once
weekly for the duration of the experiment to support
the growth of the estrogen-dependent MCF-7 tumors.
The cells were inoculated subcutaneously at 1.1 × 10
6
cells per inoculum on one flank in a final volume of
200 μL containing 100 μL of Matrigel (BD Biosciences,
San Jose, CA, USA) and 100 μL of cells suspended in
0.9% NaCl.
Twenty days after the cell inoculation, the mice
received the CTet intraperitoneally at the concentration
o f5m g / k gp e rd a yf o r5d a y sp e rw e e kf o rat o t a lo f
2 weeks. The mice in the control (placebo) group
received the same volume of the vehicle as the CTet-
treated mice. At least four animals were studied for
each experimental group. Each xenograft was monitored
by using a calliper to externally measure tumors in two
dimensions. Tumor volume (in cubic millimeters) was
calculated as a
2 × b ×0 . 5 ,w h e r ea is the length and b
is the width of the tumor.
Statistical analyses
Data are expressed as mean ± standard error of the
mean of at least three separate experiments. The half
inhibitory concentration (IC50) values of antiproliferative
activity were calculated by nonlinear regression by using
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(HillSlope)/(IC50
(HillSlope) +
x
(HillSlope)) (Prism5; GraphPad Software, Inc., La Jolla,
CA, USA). Statistical analysis was performed by using
the Mann-Whitney test or one-way ANOVA followed
by Tukey post hoc test as appropriate (Prism5).
Results
Synthesis of CTet
The protocol herein reported to obtain CTet was opti-
mized in terms of reagents, temperature, and time. The
d e v e l o p e dm e t h o dp r o v e dt ob er e p r o d u c i b l ew i t h
regard to CTet/CTr ratio and yield (Additional file 1,
CTr formation).
Antiproliferative activity of CTet
It has been previously reported that CTet formulated
with g-CD is able to inhibit proliferation of both MCF-7
and MDA-MB-231 breast cancer cell lines [21]. In this
study, we confirm the dose-dependent activity of CTet
in both MCF-7 (IC50 = 1.32 ± 0.03 μM) and MDA-MB-
231 (IC50 = 1.00 ± 0.01 μM). In addition, we investi-
gated the drug effect on DNA synthesis in two other
breast cancer cell lines: BT474 (ER
+) and BT-20 (triple-
negative) (Figure 2). The IC50 values obtained in the
two cell lines were 2.64 ± 0.28 and 6.69 ± 0.37 μM,
respectively.
Analysis of cell cycle perturbations
Cell cycle analysis was carried out in MCF-7 and MDA-
MB-231 to evaluate the effect of CTet on cell cycle pro-
gression. Cells were treated with CTet for 24 and 48 hours
at the final concentrations of 4.0 and 8.0 μMa n dt h e n
stained with propidium iodide for flow cytometric ana-
lyses. Results showed that CTet induced G2/M accumula-
tion in both MCF-7 and MDA-MB-231 cells (Figure 3).
After 48 hours of treatment, the cellular population in the
G2/M phase significantly increased from 19.7% ± 0.9%
to 25.4% ± 0.9% in MCF-7 and from 19.5% ± 1.5% to
26.1% ± 0.6% in MDA-MB-231 (P < 0.05).
CTet-treated MDA-MB-231 cells show morphological
features of autophagy
Although the exposure of breast cancer cells to CTet
failed to induce apoptosis, specific morphological fea-
tures of autophagy were detectable in drug-treated
MDA-MB-213 cells. In particular, in cells exposed at
different time points to 8.0 μM CTet, the occurrence of
autophagy was assessed by immunofluorescence analysis
of LC3b protein. The LC3b protein is recruited to the
autophagosome membrane during the autophagy pro-
cess; consequently, changes in the intracellular localiza-
tion of LC3b provide a reliable molecular marker for the
detection of autophagy. A significant increase in the per-
centage of MDA-MB-231 cells with a characteristic
punctate pattern of LC3b expression was appreciable
following exposure to CTet (Figure 4a). Fusion between
autophagosomes and lysosomes also represents an
important regulatory step of autophagy pathway and
can be monitored by co-localization of LC3b and lyso-
some markers LAMP1 or LAMP2a. In MDA-MB-231
cells, autophagic vescicles were found to co-localize
with lysosome after exposure to CTet, as demonstrated
by the overlapping of LC3b and LAMP2a signals in
combined immunofluorescence experiments (Figure 4b;
Additional file 2, Figure S1). Taken together, these
results indicate that autophagic lysosomal activity is
significantly upregulated in MDA-MB-231 as a conse-
quence of CTet exposure. Autophagy features have
been transiently observed also in MCF-7 cells following
exposure to the highest CTet concentration (data not
shown).
Changes of gene expression profile induced by CTet in
MCF-7 and MDA-MB-231 cell lines
The molecular mechanisms involved in CTet response
in MCF-7 and MDA-MB-231 cells lines were investi-
gated by means of microarray technology. Both cell lines
were treated with 6.0 and 12.0 μM CTet for 24 hours
before cell harvesting. This early time point was chosen
with the aim of observing the changes in gene expres-
sion before they have an effect on cell metabolism.
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Figure 2 Antiproliferative activity of the CTet formulated in
g-cyclodextrin aqueous solution. Estrogen receptor-positive
(MCF-7 and BT-474) and triple-negative (MDA-MB-231 and BT-20)
human breast cancer cell lines were exposed to increased
concentrations of CTet. Cell proliferation was evaluated by [
3H]
thymidine incorporation into cellular DNA after 72 hours of
treatment. Results are shown as the percentage of [
3H]thymidine
incorporation in treated cells compared with control cells (vehicle
only). Data are expressed as mean ± standard error of the mean of
at least three separate experiments. CTet, indole-3-carbinol cyclic
tetrameric derivative.
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responses of CTet were similar among cell lines and
independent from the hormonal receptor status, the
genes sharing a common expression pattern in both
MCF-7 and MDA-MB-231 cell lines, in either 6.0 or
12.0 μM CTet treatment conditions, were selected with
GeneSifter software.
First, when a differential expression cutoff of 2
(ANOVA, Benjamini-Hochberg false discovery rate cor-
rection, P < 0.01) was used, a total of 960 genes differen-
tially expressed in at least one treatment in MCF-7 or
MDA-MB-231 cells (or both) were identified. Then, a
further analysis of the expression pattern in this subset of
genes (Pearson uncentered correlation coefficient of 0.98)
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Figure 3 Cell cycle effects of the CTet in MCF-7 and MDA-MB-231 cell lines. DNA content profiles of cells that were exposed for 24 and
48 hours to 4 and 8 μM CTet or g-cyclodextrin solution (CTR), stained with propidium iodide, and analyzed by flow cytometry are shown. Data
are from one representative experiment. The percentages of cells in the different phases of the cell cycle are presented as the mean of three
experiments ± standard error of the mean. Asterisks indicate statistically significant values with respect to CTR (one-way analysis of variance
followed by Tukey post hoc test; P < 0.05). CTet, indole-3-carbinol cyclic tetrameric derivative.
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Figure 4 Morphological features of autophagy in CTet-treated MDA-MB-231 cells. Autophagy induction in MDA-MB-231 cells following
exposure to CTet was detected by recruitment of LC3b protein to autophagosomes (a) and fusion between autophagosomes and lysosomes in
terms of co-localization of LC3b and the lysosome marker LAMP2a (b). CTet, indole-3-carbinol cyclic tetrameric derivative; CTR, control; LAMP2a,
lysosome-associated membrane protein type 2a; LC3b, microtubule-associated protein 1 light chain 3.
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Page 8 of 15revealed that 116 genes were upregulated (search pattern:
control = 1; 6.0 μM >1; 12.0 μM >2) and 177 genes were
downregulated (search pattern: control = 1; 6.0 μM< 1 ;
12.0 μM < 0.5) in both cell lines (Additional files 3 and
4, Tables S1 and S2, respectively). To explore the biologi-
cal significance of the transcriptome response shared by
the two cell lines, z-score reports containing the most
significant GO terms were generated from the commonly
upregulated (Table 1) and downregulated (Table 2)
genes. Criteria for selection were GO terms containing at
least 20 genes, number of genes differentially expressed
within the assigned ontology of at least 3, and z-score of
at least 4 or not more than -4. The ontology list was
then pruned by hand for related GO terms to remove
any over-represented branches of the GO hierarchy.
When both a parent and a child term were present on
the list, the parent term was removed if its presence was
due entirely to genes meeting the criterion for the child
term.
Concerning the upregulated genes, the main terms in
the biological process category included ‘response to sti-
mulus’ (stress, chemical stimulus, extracellular stimulus,
and so on), ‘apoptosis’, ‘protein folding’, and ‘autophagy’.
The cellular components were linked to ‘autophagic
vacuole’ and ‘integral to membrane’, the latter having a
number of differentially expressed genes lower than
expected by chance (negative z-score; Materials and
methods). In the molecular function category, tran-
scripts were linked to ‘heat shock protein binding’,
‘unfolded protein binding’,a n d‘antioxidant activity’
(Table 1).
With respect to downregulated genes, the biological
process category included ‘cell cycle’ and ‘DNA meta-
bolic process’, whereas the cellular components were
linked to ‘chromosomal part’. Finally, the molecular
functions category included ‘transmembrane receptor
protein tyrosine kinase activity’, ‘DNA helicase activity’,
and ‘insulin-like growth factor binding’ (Table 2).
To further verify the microarray transcription profile
results, selected genes were analyzed by quantitative RT-
PCR. For these analyses, three genes associated with cell
cycle arrest were selected: p27/CDKN1B (already identi-
fied by using CTet previously prepared [20]), GADD45A,
and p21/CDKN1A (identified as g-CD-formulated
Table 1 Selected ontologies of commonly upregulated
genes
Term Genes
a Gene set on
the array
Z-
score
Biological process
Response to stimulus 39 3,137 4.82
Response to stress 27 1,753 5.05
Response to unfolded protein
b 3 62 4.14
Acute inflammatory response
b 5 99 5.5
Acute-phase response
b 4 43 7.11
Regulation of acute inflammatory
response
b
3 26 6.95
Response to chemical stimulus 21 1,396 4.26
Response to organic substance
b 15 845 4.25
Response to hormone stimulus
b 10 440 4.35
Response to steroid hormone
stimulus
b
7 220 4.75
Response to glucocorticoid
stimulus
b
6 94 6.98
Leukocyte chemotaxis
b 3 60 4.23
Response to oxygen levels
b 5 151 4.12
Response to toxin
b 3 64 4.05
Response to extracellular stimulus 7 242 4.41
Positive regulation of response to
external stimulus
b
4 87 4.63
Cellular response to extracellular
stimulus
b
5 82 6.19
Cellular response to nutrient
levels
b
4 62 5.73
Cellular response to starvation
b 3 43 5.2
Response to biotic stimulus 10 424 4.49
Response to virus
b 6 147 5.24
Cell death 24 1,227 6.04
Apoptosis 22 1,116 5.8
Regulation of cell death
b 17 872 4.99
Regulation of apoptosis
b 16 859 4.62
Negative regulation of cell death
b 10 402 4.69
Negative regulation of apoptosis
b 9 391 4.16
Induction of apoptosis
b 8 333 4.06
Anti-apoptosis
b 8 226 5.49
Positive regulation of anti-
apoptosis
b
3 32 6.18
Cellular component disassembly
involved in apoptosis
b
3 27 6.81
Release of cytochrome c from
mitochondria
b
3 24 7.27
Protein folding 6 158 4.99
Leukocyte migration 4 86 4.66
Autophagy 3 48 4.86
Regulation of synaptic plasticity 3 57 4.37
Iron ion homeostasis 4 31 8.54
Positive regulation of smooth
muscle cell proliferation
3 28 6.67
Regulation of viral reproduction 3 28 6.67
Cellular component
Integral to membrane 9 4,459 -4.27
Autophagic vacuole 3 20 8.2
Table 1 Selected ontologies of commonly upregulated
genes (Continued)
Molecular functions
Heat-shock protein binding 5 71 7.14
Unfolded protein binding 5 103 5.69
Antioxidant activity 3 45 5.35
aNumber of genes differentially expressed within the assigned ontology.
bSubcategory within a given ontology.
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Page 9 of 15CTet-induced genes in the microarray experiments).
GAPDH was used as a housekeeping gene. Actin-b was
used in a subset of samples (not shown) as an alternative
housekeeping gene to confirm the results obtained with
GAPDH. The results (Figure 5) were almost superimposa-
ble with those of the microarray experiments, although a
greater sensitivity of RT-PCR compared with microarray
analysis was revealed. p27/CDKN1B gene expression
appeared unchanged, whereas p21/CDKN1A showed
upregulation in all conditions tested in both cell lines.
Moreover, a significant upregulation of GADD45A gene
was observed in both MCF-7 and MDA-MB-231 cell
lines, although the microarray experiment did not show
any significant upregulation in the latter cell line. The
quantitative RT-PCR analysis has also been performed on
two new sets of biological samples, from either MCF-7 or
MDA-MB-231 cells, confirming the upregulation of p21/
CDKN1A and GADD45A. The average data obtained
from three biological samples are shown in Figure S2 of
Additional file 5.
Immunoblot analysis
The significant upregulation of p21/CDKN1A CDKs
inhibitor gene, monitored by microarray studies, was
further investigated at the protein level by immunoblot
analysis. The results showed that p21/CDKN1A was
overexpressed in both MCF-7 and MDA-MB-231 cell
lines after 24 hours of treatment (>7-fold to actin) and
in MCF-7 cells after 48 hours of treatment (>9-fold to
actin) (Figure 6). Unlike in previous results [20], CTet
formulated did not induce p27
kip1 (cyclin-dependent
kinase inhibitor 1B) overexpression in MCF- 7 and
MDA-MB-231 cells. Further investigations were there-
fore directed to establish the involvement of FOXO3a
transcription factor localization and Akt activity, both of
which are involved in p21/CDKN1A expression [28,29].
To evaluate the role of the PI3K/Akt pathway in p21/
CDKN1A expression in CTet-treated breast cancer cell
lines, Akt activity was detected by using a specific anti-
phospo-Akt antibody, the phosphorylated form of Akt
protein. The results showed that, in both MCF-7 and
MDA-MB-231, phospho-Akt decreases after 48 hours of
treatment (about 0.8-fold and 0.6-fold to total-Akt in
MCF-7 and MDA-MB-231, respectively), whereas the
decrement of the cytosolic fraction of phospho-Akt was
observed after 24 hours of treatment (about 0.6-fold and
0.4-fold to total-Akt in MCF-7 and MDA-MB-231,
respectively) (Figure 6). Akt can inactivate FOXO3a via
phosphorylation and subsequent translocation to cyto-
sol, but in CTet-treated cells, there was no evidence of
variation in FOXO3a localization, suggesting that this
transcription factor was not involved in the overexpres-
sion of p21/CDKN1A.
Effect of CTet on xenograft tumor growth in athymic
nude mice
Toxicity studies aimed at establishing median lethal dose
(LD50) showed that CTet in the concentration range of
0.5 to 15 mg/kg did not cause any toxic effect (data not
shown). To evaluate the potential therapeutic efficacy of
systemic administration of CTet, a preliminary experi-
ment was performed in human breast cancer xenograft-
bearing nude mice. The MCF-7 cells were inoculated
subcutaneously on one flank of nude mice as described
in Materials and methods. Twenty days after cell inocu-
lation, intraperitoneal treatment with CTet was started
at the dose of 5 mg/kg per day (five treatments a week)
a n dl a s t e df o r2w e e k s .T h er e s u l t ss h o w e dt h a tt h e
treatment blocked the increase of tumor mass, which
significantly increased in the animals either not treated
or receiving the vehicle (Figure 7). After 2 weeks of
treatment, both mice groups receiving CTet or the vehi-
cle did not show any alteration either in body weight or
in the hematological parameters with respect to the
untreated mice (data not shown).
CTet activity in different storing conditions
CTet activity in different storing conditions was evalu-
ated up to 1 year. Aliquots of CTet were stored at dif-
ferent conditions of temperature and light exposition
(Additional file 6, Table S3), and the activity was evalu-
ated in MCF-7 at different time points (4, 8, 12, and
20 weeks and after 1 year). The results showed that the
antiproliferative activity, expressed as IC50,r e m a i n s
Table 2 Selected ontologies of commonly downregulated
genes
Term Genes
a Gene set on
the array
Z-
score
Biological process
Cell cycle 20 957 4.42
Spindle organization
b 4 54 5.31
DNA metabolic process 18 559 6.32
DNA replication
b 13 228 8.13
DNA-dependent DNA replication
b 5 71 5.75
DNA-dependent DNA replication
initiation
b
3 25 6.13
Cellular component
Chromosomal part 13 381 5.57
Condensed chromosome
kinetochore
b
4 69 4.52
Replication fork
b 3 33 5.2
Molecular function
Transmembrane receptor protein
tyrosine kinase activity
4 64 4.81
DNA helicase activity 3 41 4.6
Insulin-like growth factor binding 3 24 6.32
aNumber of genes differentially expressed within the assigned ontology.
bSubcategory within a given ontology.
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Table S3). Chemical stability of the molecule was assessed
by HPLC after 1 year of storage. The chromatographic
profile showed that, in all light-protected conditions, more
than 95% of the CTet maintained its chromatographic
behavior, confirming the biological data; however, in non-
light-protected conditions, a loss of the molecular integrity
(~15%) was detected (data not shown).
Discussion
In the last decades, the mortality rates of breast cancer
have decreased [30] as a result of implementation of
screening [31], improvements in the local management
of early breast cancer [32], and the introduction of adju-
vant systemic treatments [33]. However, breast cancer is
the leading cause of cancer-related death for women in
Europe and the US [34,35]. The treatment of a subgroup
of breast tumors resistant to targeted therapies - named
triple-negative tumors because of a lack of estrogen,
progesterone, and HER2/Neu receptors - is a problem
that remains unsolved [1,2].
Derivatives of I3C with good antiproliferative activity
independently of hormonal receptor status have been
widely studied in recent years [7,8,17-19,36]. The poten-
tial of one of these molecules, the I3C cyclic tetrameric
derivative CTet, in the inhibition of breast cancer cell
proliferation was shown [20]. However, further analysis
revealed that, owing to the presence of other oligomeric
derivatives of I3C, the synthetic method previously
reported did not give a pure compound.
Recently, Lucarini and colleagues [21] proposed a
straightforward synthesis of CTet, but this method, as
well as the others reported in the literature [20,37,38], is
not sufficiently advantageous. In this paper, we describe
a new synthesis involving 2,3’-DIM homo-coupling in
t h ep r e s e n c eo ff o r m a l d e h y d ei na c i d i cm e d i u m .T h i s
synthetic procedure gave an acceptable CTet yield,
higher than those already reported [20,21,37,38].
The antiproliferative activity of CTet formulated with
g-CD, first evaluated in MCF-7 and MDA-MB-231
[21], was confirmed in this study in two additional
breast cancer cell lines (BT-474 and BT-20), showing
that CTet is able to inhibit cell proliferation about 10-
fold more than the first formulation in all cell lines
tested.
The cell cycle and molecular analyses in MCF-7 and
MDA-MB-231 cells treated with formulated CTet did
not show the induction of G1 cell cycle arrest or the
overexpression of CDKs p27 inhibitor as described pre-
viously [20]. In fact, CTet inhibited cell proliferation by
activating mechanisms resulting in an increased amount
of viable cells in the G2/M phase of the cell cycle.
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Figure 5 Gene expression analysis of p27, p21, and GADD45A. Quantitative real-time polymerase chain reaction (gray bars) and microarray-
based (black bars) expression analyses of p27, p21, and GADD45A genes were carried out in MCF-7 and MDA-MB-231 cell lines treated with
CTet 6.0 μM (left) and 12.0 μM (right) for 24 hours. For quantitative real-time polymerase chain reaction, GAPDH was used as a housekeeping
gene. Data are shown as mean ± standard deviation. Asterisks indicate statistically significant values (P < 0.01). GADD45A, growth arrest and
DNA-damage-inducible protein alpha; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Page 11 of 15Autophagy is a multistep process in which cellular
proteins and organelles are sequestered, delivered to
lysosomes, and digested by lysosomal hydrolases. This
process culminates when the nascent autophagosome
fuses with the endosomal/lysosomal system to create a
fully functional degradative compartment, the autolyso-
some. By a combined immunofluorescence approach, we
were able to detect such a fusion in CTet-treated MDA-
MB-231 cells as the co-localization of the autophago-
some marker LC3b and the lysosomal marker LAMP2a
[39]. Whether treatment-induced autophagy in these
cells represents a survival mechanism or initiates a non-
apoptotic cell death remains uncertain [40]. However,
the evidence of a significant drug-induced antiprolifera-
tive effect in the absence of a clear activation of apopto-
tic pathways, as observed in gene expression analysis
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Figure 6 Cell viability and immunoblot analyses in CTet-treated MCF-7 and MDA-MB-231 breast cancer cell lines. Cells were treated for
24 and 48 hours with 6.0 and 12.0 μM CTet or vehicle only (g-cyclodextrin aqueous solution). After treatments, cell viability was evaluated by
Trypan blue dye exclusion assay and cell extracts were processed as described in the Materials and methods (’Immunoblot analysis’). Akt activity
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mean of three separate experiments. Asterisks indicate statistically significant values with respect to untreated cells (one-way analysis of variance
followed by Tukey post hoc test; P < 0.01). Blots are representative of at least two separate experiments. CTet, indole-3-carbinol cyclic tetrameric
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Page 12 of 15(see below), would suggest the possibility that MDA-
MB-231 cells undergo autophagic cell death.
From gene expression analysis, a reliable list of genes
upregulated or downregulated in response to CTet treat-
ment was obtained. Interestingly, several genes involved
in suppression of cell proliferation resulted upregula-
ted (for example, IL6, IL8, p21/CDKN1A,a n dHBP1)
whereas other genes involved in cell cycle progression
were downregulated (for example, CDK2, CCNE2, E2F2,
MCM3, and PKMYT1), recapitulating the cell cycle pro-
file alterations observed.
The gene expression analysis revealed also the cellular
response to the stress/stimulus induced by the drug
treatment, through the upregulation of genes involved
in oxidative stress response (for example, HMOX1,
TXNRD1,a n dSOD2), xenobiotic metabolism, (for
example, CYP1B1, AKR1C1,a n dAHR), response to
unfolded proteins (for example, DNAJB1, DNAJB4,
DNAJB9,a n dHSPA1A), and inflammatory response (for
example, IL6, CEBPB, CCL5, PTGS2,a n dCFB). More-
over, the upregulation of either pro-apoptotic (for exam-
ple, BBC3, DEDD2,a n dPMAIP1) or anti-apoptotic
(for example, BAG3 and BEX2)g e n e sd on o tp r o v i d e
evidence of any apoptosis induction. In addition, micro-
array results supported (from a molecular point of
view) the autophagy process observed in both cell lines.
In fact, the autophagy-related genes WIPI1 (ATG18),
GABARAPL1 (ATG8), MAP1LC3B (LC3B), and SQSTM1
were found upregulated. Moreover, RT-PCR results,
besides confirming the upregulation of p21/CDKN1A,
showed a significant upregulation of GADD45A gene also
in MDA-MB-231 cells.
Altogether, our results suggest that the genes responsi-
ble for the arrest of cell proliferation could be the p21/
CDKN1A and GADD45A. The p21 protein is a universal
inhibitor of the cyclin-dependent kinase (CDK) family
[41] and is able to block cell cycle progression in either
the G1/S or the G2/M phase [41-44]. GADD45A interacts
with Cdc2 and inhibits its kinase activity, playing an
important role in the regulation of the G2/M cell cycle
checkpoint [45,46]. This finding suggests that CTet treat-
ments inhibit cell cycle progression in breast cancer cells
by acting on both G1/S and G2/M cell cycle checkpoints.
The upregulation of p21/CDKN1A and GADD45A has
to be considered not dependent by p53 induction since
p53 gene is mutated in MDA-MB-231 cells [47,48].
Moreover, a search for the important transcription fac-
tor-binding sites enriched in the selected 116 commonly
upregulated genes (Table 4S) by using Distinct Regula-
tory Elements of co-regulated genes (DiRE) algorithm
[49,50] did not show the presence of p53 among the top
50 transcription factors identified (data not shown).
The immunoblot analysis also revealed the inhibition
of Akt activity in both cell lines tested. The protein
kinase components of protein kinase B (Akt) pathway
represent one set of potential targets for treatment of
triple-negative tumors [2]. In fact, PI3K and downstream
AKT/protein kinase B family members have been impli-
cated in several cell responses, including the protection
of cells from apoptosis, the promotion of cell prolifera-
tion, and different metabolic responses [3], and may also
be implicated in both p53-dependent and p53-indepen-
dent expression of p21/CDKN1A [28] and GADD45A
[51]. The inhibition of Akt activity could then play a
central role in the antitumoral properties of CTet, as
well as I3C and 3,3’-DIM [9-11], and could explain, at
least in part, the induction of p53-independent p21/
CDKN1A and GADD45A overexpression in the p53
mutant MDA-MB-231 cell line.
The mechanisms by which CTet-induced overexpression
of p21/CDKN1A and GADD45A, resulting in the inhibi-
tion of cell proliferation and autophagy, will be further
investigated to establish the eventual involvement of
upstream PI3K/AKT or other molecular pathways or both.
The in vivo biological activity of the g-CD-formulated
CTet was promising since the administration was effec-
tive in blocking the increase of tumor mass in xenograft
study. Moreover, neither CTet formulation nor g-CD
aqueous solution alone showed toxicity.
CTet stored in the dark is a very stable molecule.
Indeed, more than 98% of CTet formulated in g-CD
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Figure 7 In vivo effects of CTet on the growth of human MCF-7
breast cancer cell-derived tumors from xenografts in athymic
mice. Athymic female mice were inoculated with MCF-7 cells and
then intraperitoneally treated with CTet (5 mg/kg) or vehicle
(g-cyclodextrin solution) for 2 weeks, as described in Materials and
methods. The percentage of residual tumor mass has been
calculated with respect to time 0, which corresponds to the start of
treatment. Positive control (CTR) refers to four mice bearing the
tumor and not treated, CTR + vehicle refers to four mice bearing
the tumor and receiving the vehicle, and CTR + CTet refers to five
mice bearing the tumor and receiving CTet. The results are
presented as mean ± standard deviation of the number of mice
indicated above. The asterisk indicates statistically significant value
with respect to CTR and CTR + vehicle (Mann-Whitney test;
P < 0.05). CTet, indole-3-carbinol cyclic tetrameric derivative.
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Page 13 of 15aqueous solution and stored at room temperature and
protected from light retained its stability and biological
activity up to 1 year (IC50 <1 μM) in MCF-7 cells. On
the whole, the results obtained with g-CD formulated
C T e ta r ev e r yi m p o r t a n tb e c a u s et h eu t i l i z a t i o no f
dimethyl sulfoxide as a vehicle is not needed [17,20,36].
Conclusions
Our results showed that CTet is able to induce G2/M
cell accumulation and autophagic response in both hor-
mone-responsive and triple-negative breast cancer cells.
The overexpression of p21/CDKN1A could be the main
molecular event responsible for the inhibition of cell
proliferation, together with the inhibition of Akt activity
and the overexpression of GADD45A and the autop-
hagy-related genes. Results from the in vivo study also
showed that CTet formulated with g-CD is a promising
and injectable anticancer agent that deserves additional
studies to support the data reported here.
Additional material
Additional file 1: CTr formation. Plausible mechanisms of CTr
formation in the CTet synthesis.
Additional file 2: Figure S1. Autophagic morphological features
induced by serum starvation in MDA-MB-231 cells (positive control)
detected by fusion between autophagosomes and lysosomes, in terms
of co-localization of LC3b and the lysosome marker LAMP2a.
Additional file 3: Table S1. Transcriptome analysis was performed on
MCF-7 and MDA-MB-231 cells treated with 6.0 μM and 12.0 μM CTet for
24 hours. The genes up-regulated in both MCF-7 and MDA-MB-231 cell
lines, either in 6.0 μM and 12.0 μM CTet treatment conditions, were
selected using GeneSifter software. The software analysis allowed to
identify a list of 116 genes significantly (p < 0.01) up-regulated in both
cell lines.
Additional file 4: Table S2. Transcriptome analysis was performed on
MCF-7 and MDA-MB-231 cells treated with 6.0 μM and 12.0 μM CTet for
24 hours. The genes down-regulated in both MCF-7 and MDA-MB-231
cell lines, either in 6.0 μM and 12.0 μM CTet treatment conditions, were
selected using GeneSifter software. The software analysis allowed to
identify a list of 177 genes significantly (p < 0.01) down-regulated in
both cell lines.
Additional file 5: Figure S2. Quantitative real-time PCR of p27, p21 and
GADD45A genes were carried out in MCF-7 and MDA-MB-231 cell lines
treated with CTet 6.0 μM (left) and 12.0 μM (right) for 24 hours. Data are
shown as mean ± standard deviation of three separate experiments.
Asterisks indicate statistically significant values (p < 0.01).
Additional file 6: Table S3. Antiproliferative activity of CTet in different
storing conditions in MCF-7 cells. Aliquots of CTet were stored at
different conditions of temperature and light exposition and the activity
was then evaluated in MCF-7 at different time points (4, 8, 12, 20 weeks
and after one year). Results are reported as IC50 values.
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